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Abstract
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet.
Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of
bevacizumab.
Methods: Genomic DNA of 111 consecutive metastatic colorectal cancer patients treated with first-line FOLFIRI
plus bevacizumab was obtained from blood samples. VEGF -2578 C/A, -1498 C/T, + 405 C/G, + 936 C/T
polymorphisms were analyzed by means of PCR-RFLP. DNA samples from 107 patients treated with FOLFIRI alone
served as historical control group. The relation of VEGF polymorphisms with PFS, evaluated through Kaplan-Meier
method and log-rank test, was the primary end-point. An interaction test with a Cox model has been performed in
order to demonstrate the heterogeneity of the effect of VEGF -1498 C/T polymorphism between bevacizumab-and
control group.
Results: In the bevacizumab-group median PFS and OS of patients carrying VEGF -1498 C/C, C/T and T/T allelic
variants were, respectively, 12.8, 10.5, 7.5 months (p = 0.0046, log-rank test) and 27.3, 20.5, 18.6 months (p = 0.038,
log-rank test). VEGF -1498 T/T genotype was associated with shorter PFS (HR = 2.13, [1.41-5.10], p = 0.0027). In the
control group no significant association of VEGF -1498 C/T allelic variants and PFS or OS was found. Interaction
between VEGF -1498 C/T variants and treatment effect suggested that the relation of VEGF -1498 T/T genotype
with shorter PFS was caused by the effect of bevacizumab (p = 0.011). Other investigated polymorphisms did not
affect the outcome.
Conclusions: These data suggest a possible role for VEGF -1498 C/T variants in predicting the efficacy of
bevacizumab in the up-front treatment of metastatic colorectal cancer patients. A molecular tool for selecting
subjects candidate to benefit from the anti-VEGF could be important for clinical practice. The retrospective and
exploratory design of the present study, coupled with the non-randomized nature of the comparison between
treated and untreated patients, imply that these results should be considered as hypothesis generators. A
prospective validating trial is currently ongoing.
* Correspondence: fotiosloupakis@gmail.com
1U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria
Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti
e delle Nuove Tecnologie in Medicina, Università di Pisa, Italy
Full list of author information is available at the end of the article
Loupakis et al. BMC Cancer 2011, 11:247
http://www.biomedcentral.com/1471-2407/11/247
© 2011 Loupakis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
The therapeutic approach to metastatic colorectal can-
cer (mCRC) patients has progressively changed in the
last few years, thanks to the introduction of biologic
drugs in the daily practice, such as cetuximab, a mono-
clonal antibody (MoAb) directed against the epidermal
growth factor receptor (EGFR), and bevacizumab, a
MoAb that blocks the vascular endothelial growth factor
(VEGF) [1].
While it has been proven that cetuximab is not active
in patients bearing KRAS mutant tumours [2,3], even if
a recent analysis suggests that this could not be true for
G13D mutations [4], up today there are no predictive
biomarkers of bevacizumab efficacy. Therefore the anti-
VEGF MoAb therapy is currently approved for the treat-
ment of mCRC in association with fluoropyrimidine-
based chemotherapy without any molecular selection
[5].
Bevacizumab has a well-known toxicity profile causing
adverse events such as bleeding, gastrointestinal perfora-
tion, arterial and venous thromboembolism, hyperten-
sion, proteinuria and wound-healing complications [6,7].
Hence, possible predictors of the efficacy of bevacizu-
mab are needed to avoid serious adverse events at least
in those patients with low chances of benefit. Up to
now such determinants have not been individuated yet,
despite several attempts [8-10]. Moreover, it should be
considered that for KRAS wild-type patients the knowl-
edge ap r i o r iof an intrinsic resistance to bevacizumab
would lead the therapeutic choice toward the alternative
option of administering the anti-EGFR cetuximab.
Many studies have demonstrated that specific VEGF
single nucleotide polymorphisms (SNPs) may affect gene
transcription with a consequent variable production of
VEGF and a putative effect on pathogenesis as well as
on evolution of disorders in which angiogenesis is criti-
cal [11-14]. The predictive and prognostic role of some
VEGF SNPs has been retrospectively investigated in
genomic DNA-since it has been demonstrated that the
host angiogenic genotype imprints the tumor genotype
[15]-of metastatic breast [16], ovarian [17], pancreatic
[18] and colon cancer [19] patients treated with bevaci-
zumab. The results regarding different polymorphisms
were heterogeneous, inconclusive and inapplicable to
clinical practice and often lacked of a comparison with
an untreated control group. Nevertheless, it should be
considered that the effect of specific genetic variants
may differ among different diseases as well as on the
basis of which chemotherapy is administerd together
with the anti-VEGF. On the basis of such considera-
tions, we conducted a retrospective study in order to
investigate the role of four VEGF SNPs in predicting the
efficacy of bevacizumab added to FOLFIRI as first-line
treatment of mCRC patients [11,13]. The selected
polymorphisms were: -2578 C/A (rs699947) and -1498
C/T (rs833061) in the promoter region; + 405 G/C
(rs2010963) in the 5’ untraslated region (UTR) and +
936 C/T (rs3025039) in the 3’ UTR. Such allelic variants
were assessed both in a population who had received
FOLFIRI plus bevacizumab as first-line regimen (bevaci-
zumab-group) and in a historical cohort of patients trea-
ted with FOLFIRI only in order to evaluate the possible
interaction between VEGF SNPs and treatment effect.
Methods
Study population
Consecutive patients with histologically confirmed,
metastatic colorectal adenocarcinoma receiving first-line
FOLFIRI plus bevacizumab in 5 Italian Oncology Units,
from December 2005 until November 2008 were
included in the bevacizumab-group. The following basal
characteristics were collected: sex, age (≤ or > 65 years),
ECOG performance status (PS), primary tumor site
(colon or rectum), surgery on primary tumor (yes or
no), mucinous histology (yes or no), previous adjuvant
chemotherapy (yes or no), time to metastases (synchro-
nous or metachronous), number of involved organs (sin-
gle or multiple), liver-only metastases (yes or no),
baseline haemoglobin level (< or ≥ 11 g/dl), baseline leu-
kocytes number (> or ≤ upper limit of normal, ULN),
baseline lactate dehydrogenase (> or ≤ ULN), baseline
alkaline phosphatase (> or ≤ ULN), baseline albumin
level (< or ≥ lower limit of normal), baseline carcinoem-
bryonic antigen (CEA, < or ≥ 100 ng/ml) and Köhne
prognostic score [20].
A historical cohort of 107 patients treated from Janu-
ary 2001 until November 2006 with first-line FOLFIRI
alone served as control group.
According to RECIST criteria version 1.0 [21], all
patients were evaluated for response, progression free
survival (PFS) and overall survival (OS). Bevacizumab-
related toxicities were reported according to National
Cancer Institute Common Terminology Criteria version
3.0 (NCI-CTCAEv3.0) [22].
Blood samples stored at -20°C were available for mole-
cular analyses. Patients’ written informed consent was
required before entering the study.
The study was approved by local Ethic Committee.
Genotyping
Genomic DNA was extracted from 1 ml of peripheral-
blood samples using the “salting out” method [23].
VEGF -2578 C/A (rs699947), -1498 C/T (rs833061), +
405 C/G (rs2010963) and + 936 C/T (rs3025039) poly-
morphisms were investigated by means of polymerase
chain reaction-restriction fragment lenght polymorphism
(PCR-RFLP) technique (primers’ sequences and restric-
tion enzymes are specified in Table 1). Genotyping was
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clinical outcome.
Statistical Analysis
The primary end-point of this retrospective analysis was
the relation of VEGF polymorphisms with PFS. The sec-
ondary end-point were the relation with OS, response
rate (RR) and toxicity. PFS was defined as the time from
the beginning of the treatment until the first observation
of disease progression or death from any cause. Patients
who underwent secondary radical surgery on metastases
were censored at the time of surgery. OS was defined as
the time from the beginning of the treatment until
death from any cause.
All polymorphisms were examined for deviation from
Hardy-Weinberg equilibrium (HWE) by comparing
actual allelic distributions with those expected from
HWE using a c2-test.
A two-sided Fisher’s exact test was used to evaluate the
association of investigated genotypes and toxicities with
RR. In both groups, Kaplan-Meier method and log-rank
test were adopted to conduct an explorative analysis with
the aim of estimating the importance of each clinical,
pathological and genomic feature in predicting Hazard
Ratios (HR) for progression and death. The most relevant
covariates (those showing a p value < 0.10) were used to
fit a Cox proportional hazard model. The heterogeneity
of the effect of VEGF -1498 C/T polymorphism between
bevacizumab-and control group was explored by using a
statistical test for interaction, applied through a Cox
model for PFS and OS. Inference on parameters of the
Cox model was obtained using nonparametric bootstrap
with 20000 Monte Carlo replications.
Results
One-hundred eleven patients were included in the beva-
cizumab-group and received bevacizumab in combina-
tion with FOLFIRI [24] every two weeks. Patients’
clinical characteristics and genotype frequencies are
resumed in Table 2. All analyzed polymorphisms
showed no deviation from HWE. Nine (8%), ten (9%)
and 1 (1%) patients respectively developed G1, G2 and
G3 hypertension during the treatment with bevacizu-
mab. Two bowel perforations (2%), 2 arterial (2%) and 6
venous (5%) thrombotic events were observed. Out of
111 patients, 56 were partial responders and 13 were
complete responders, for a global RR of 62%. Twenty-
nine (26%) patients obtained a disease stabilization, with
a disease control rate of 88%. At a median follow up of
13.6 months, median PFS and median OS were 10.2 and
22.2 months respectively.
Baseline characteristics of patients included in the
control group are summarized in Table 3.
Univariate Analysis
In the bevacizumab-group mucinous histology was sig-
nificantly associated with worse PFS (HR = 2.16, 95%
CI: 1.23-7.12; p = 0.015) and OS (HR = 3.21, 95% CI:
1.99-14.98; p = 0.001) (Table 2). Patients who had pre-
viously received an adjuvant chemotherapy regimen pre-
sented an increased risk for progression (HR = 1.84,
95% CI: 1.17-3.37; p = 0.011). Rectal site of primary
tumor and baseline leukocytosis predicted shorter OS
with a trend toward statistical significance (HR = 2.70,
95% CI: 0.99-4.86; p = 0.052 and HR = 2.43, 95% CI:
0.84-17.91; p = 0.083, respectively) (Table 2).
Among the analyzed VEGF polymorphisms, only -1498
C/T variants were significantly associated with survival.
No association with RR was detected. The median PFS of
patients carrying VEGF -1498 C/C, C/T and T/T allelic
variants was 12.8, 10.5 and 7.5 months respectively (p =
0.0046, log-rank test). Median OS was 27.3, 20.5 and 18.6
months respectively (p = 0.038, log-rank test) (Figure 1-
Panels A1, A2). In comparison to patients bearing VEGF
-1498 C/C genotype those with-1498 C/T and T/T var-
iants presented a higher risk of progression and death
with an additive effect of each T allele (Table 2).
Patients bearing VEGF -1498 T/T genotype had signif-
icantly shorter PFS and a trend toward worse OS com-
pared to patients carrying at least one C allele (median
Table 1 Primers and restriction enzymes used for the analysis of VEGF polymorphisms
Primers Restriction enzyme Reference SNP
VEGF -1498 C/T
F:5’-TGT GCG TGT GGG GTT GAG CG
R:5’-TAC GTG CGG ACA GGG CCT GA
BstUI rs833061
VEGF + 405 C/G
F:5’-ATT TAT TTT TGC TTG CCA TT
R:5’-GTC TGT CTG TCT GTC CGT CA
BsmFI rs2010963
VEGF -2578 C/A
F:5’-GGC CTT AGG ACA CCA TAC C
R:5’-CAC AGC TTC TCC CCT ATC C
BstYI rs699947
VEGF + 936 C/T
F:5’-AAG GAA GAG GAG ACT CTG CGC AGA GC
R:5’-TAA ATG TAT GTA TGT GGG TGG GTG TGT CAT CAG G
NlaIII rs3025039
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Characteristics N
(111)
Progression Free Survival Overall Survival
HR 95% CI P HR 95% CI p
Sex Females 54 1 1
Males 57 0.86 0.52-1.41 0.535 1.17 0.57-2.40 0.669
Age ≤ 65 years 64 1 1
>65 years 47 1.19 0.72-1.99 0.487 1.25 0.60-2.70 0.528
ECOG PS 0 102 1 1
1-2 9 0.95 0.43-2.04 0.877 0.42 0.18-1.45 0.207
Primary tumor Colon 82 1 1
Rectum 29 1.15 0.66-2.00 0.612 2.70 0.99-4.86 0.052
Mucinous histology No 96 1 1
Yes 15 2.16 1.23-7.12 0.015 3.21 1.99-14.98 0.001
Previous adjuvant CT No 66 1 1
Yes 45 1.84 1.17-3.37 0.011 1.25 0.60-2.69 0.531
Time to metastases Metachronous 50 1 1
Synchronous 61 0.67 0.40-1.09 0.103 0.93 0.44-1.95 0.849
No. of metastatic sites 15 7 1 1
>1 54 1.22 0.75-2.02 0.421 1.77 0.85-3.62 0.130
Liver-only metastases No 74 1 1
Yes 37 0.84 0.49-1.43 0.521 0.93 0.43-2.01 0.844
Resected primary tumor No 15 1 1
Yes 96 2.11 0.99-3.40 0.052 1.09 0.34-3.48 0.887
High LDH level No 69 1 1
Yes 31 0.86 0.48-1.50 0.574 1.41 0.64-3.26 0.376
Unknown 11
High CEA level No 86 1 1
Yes 23 0.69 0.39-1.20 0.183 0.65 0.28-1.61 0.375
Unknown 2
Low HgB level No 93 1 1
Yes 18 0.70 0.38-1.29 0.250 0.63 0.26-1.65 0.371
Leukocytosis No 102 1 1
Yes 9 1.29 0.55-3.19 0.526 2.43 0.84-17.91 0.083
High ALP level No 82 1 1
Yes 18 0.86 0.46-1.61 0.638 1.48 0.62-3.88 0.343
Low Albumin level No 89 1 1
Yes 8 0.93 0.38-2.30 0.874 1.25 0.26-6.43 0.757
Unknown 14
Köhne score Low 57 1 1
Intermediate-High 51 1.21 0.74-2.01 0.438 1.80 0.86-3.69 0.119
Unknown 3
-2578 A/A 16 1 1
A/C 60 1.02 0.50-2.07 0.959 1.19 0.41-3.38 0.753
C/C 35 1.53 0.74-3.26 0.246 1.36 0.42-4.65 0.581
-1498 C/C 22 1 1
C/T 60 1.82 0.98-3.55 0.056 2.49 0.98-6.16 0.056
T/T 29 2.65 1.49-6.62 0.003 2.47 0.91-7.76 0.074
+ 405 G/G 39 1 1
G/C 54 1.08 0.62-1.90 0.783 1.29 0.57-2.93 0.531
C/C 18 1.11 0.52-2.39 0.771 1.36 0.47-4.12 0.544
+ 936 T/T 21 1
C/T 31 1.38 0.35-5.38 0.642 1.60 0.27-8.47 0.645
C/C 78 1.04 0.25-4.35 0.955 1.39 0.23-7.96 0.741
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Characteristics N
(107)
Progression Free Survival Overall Survival
HR 95% CI P HR 95% CI p
Sex Females 39 1 1
Males 68 0.97 0.65-1.45 0.893 0.83 0.51-1.30 0.397
Age ≤ 65 years 60 1 1
>65 years 47 0.78 0.51-1.15 0.197 0.94 0.61-1.44 0.782
ECOG PS 08 3 1 1
1-2 24 1.34 0.84-2.31 0.196 2.32 1.68-6.23 0.0004
Previous adjuvant CT No 75 1 1
Yes 32 1.13 0.74-1.75 0.562 0.77 0.49-1.22 0.268
No. of metastatic sites 15 7 1 1
>1 50 1.10 0.75-1.62 0.632 0.88 0.57-1.34 0.542
Liver-only metastases No 68 1 1
Yes 39 0.81 0.54-1.19 0.270 0.97 0.63-1.51 0.901
High CEA level No 85 1 1
Yes 22 1.45 0.91-2.68 0.109 1.91 1.22-4.36 0.010
-1498 C/C 25 1 1
C/T 55 1.09 0.68-1.76 0.719 0.89 0.50-1.55 0.662
T/T 27 0.89 0.50-1.54 0.653 0.73 0.36-1.39 0.311
Figure 1 PFS and OS according to VEGF -1498 C/T genotypes in the bevacizumab-group (N = 111, Panels A1 and A2) and in the
control group (N = 107, Panels B1 and B2).
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= 0.0027; median OS 18.6 vs 23.1 months; HR = 1.70,
95% CI: 0.79-4.51; p = 0.155) (Figure 2).
None of VEGF allelic variants was significantly related
to specific side-effects (i.e., hypertension, arterial or
venous thrombotic events, gastrointestinal perforation).
In the control group (Table 3), among the available
clinical and pathological characteristics, only ECOG PS
and CEA levels were significantly related with OS. No
significant correlation was found with PFS. No signifi-
cant association of VEGF -1498 C/T polymorphism with
PFS or OS was detected (PFS: p = 0.662, log-rank test;
OS: p = 0.345, log-rank test) (Figure 1-Panels B1, B2)
Cox model and Interaction Test
At the multivariate analysis, in comparison to VEGF
-1498 C/-variants, T/T genotype retained its significant
association with worse PFS (HR = 2.28, 95% CI: 1.16-
4.19; p = 0.018), that translated into shorter, although
not statistically significant, OS (HR = 2.22, 95% CI:
0.54-5.51; p = 0.195) (Table 4).
Also mucinous histology retained its association with
shorter PFS (HR = 2.45, 95%CI: 1.19-4.44; p = 0.016)
and OS (HR = 4.22, 95%CI: 1.60-9.27; p = 0.009). The
interaction test between VEGF -1498 C/T variants and
treatment effect, including both bevacizumab-group and
control group, suggested that the relation of VEGF
-1498 T/T genotype with poor outcome was signifi-
cantly associated with the effect of bevacizumab in
terms of PFS (p = 0.011) and with a trend toward signif-
icance with regard to OS (p = 0.081) (Table 5).
Discussion
Targeting VEGF is an effective strategy to inhibit the pro-
cess of tumoral neoangiogenesis. Germ-line VEGF SNPs,
in particular those affecting protein levels, could theoreti-
cally become predictors of VEGF clinical efficacy.
According to the present experience among mCRC
patients treated with FOLFIRI plus bevacizumab, VEGF
-1498 T/T allelic variant is associated with significantly
shorter PFS and with a trend toward shorter OS. Such an
exploratory finding at the univariate analysis has been
confirmed in the multivariable Cox regression model.
On the other hand, no significant correlation of VEGF
-1498 C/T variants with the outcome has been found in
the historical control group. Although in terms of PFS
the interaction test is statistically significant, thus sug-
gesting that the impact of VEGF -1498 C/T SNP on the
clinical outcome might be associated with the effect of
bevacizumab, no definitive conclusions can be drawn
from such results given the non randomized nature of
the comparison. Further elusive results came from sev-
eral retrospective analyses in different metastatic dis-
eases. The retrospective study by Schneider et al. [16],
performed on specimens from advanced breast cancer
patients included in the phase III ECOG 2100 trial of
paclitaxel plus or minus bevacizumab, found an associa-
tion between VEGF -1154 A/G and -2578 A/C SNPs
and OS among patients treated with the antiangiogenic.
The interaction test confirmed the potential predictive
value of VEGF -1154 A/G, but not the one of -2578 A/
C variants [25]. However, while in ECOG 2100 trial the
benefit of the addition of the anti-VEGF to weekly pacli-
taxel was significant in terms of RR and PFS [26], VEGF
-1154 A/G SNP seems to significantly affect only OS, so
that its role as predictor of benefit from bevacizumab is
not so clear. In a phase II trial conducted in recurrent
ovarian cancer patients, treated with cyclophosphamide
and bevacizumab, a correlation between VEGF + 936 C/
T SNP and PFS has been found. In another experience,
both VEGF and VEGFR1 SNPs have been analyzed in
germline DNA from patients with metastatic pancreatic
cancer, enrolled in a phase III randomized trial of gem-
citabine and erlotinib plus or minus bevacizumab [18].
While no association of the investigated VEGF SNPs
Figure 2 P F S( A )a n dO S( B )o fp a t i e n t sw i t hVEGF -1498 T/T
versus -1498 C-genotype in the bevacizumab-group (N = 111).
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w e r er e l a t e dt oP F Sa n dO Si nt h eg r o u pt r e a t e dw i t h
the anti-VEGF MoAb.
However, although our findings do not agree with the
previous experiences in advanced breast, recurrent ovar-
ian and metastatic pancreatic cancer [16-18], it should
be taken into account that such results were obtained in
different settings of patients affected by biologically dif-
ferent diseases and treated with different cytotoxic com-
bination regimens, whose pharmacological interactions
with bevacizumab and with the host angiogenic balance
are not entirely clarified.
Concerning mCRC, a recent retrospective analysis per-
formed on blood samples from 209 patients in a phase
III trial comparing a first line treatment with FOLFIRI
plus bevacizumab versus XELIRI plus bevacizumab,
demonstrated an association of VEGF -2578 A/C and
-1154 A/G SNPs with OS [19]. Comparing our results
to the above presented study, some remarks are needed:
firstly, with regard to results in terms of OS, treatments
administered in second or subsequent lines influence
the outcome, since a remarkable percentage of patients
nowadays receive active drugs beyond the first line of
treatment and, at the same time, OS was a secondary
end-point of our analysis that was designed to look at
PFS as primary end-point. Secondly, VEGF -1154 A/G
was not tested in our study while VEGF -1498 C/T was
not investigated by the hellenic group. Finally, Koutras
et al. experience did not have any control group while
we tested two distinct cohorts, one receiving FOLFIRI
plus bevacizumab and the hystorical one treated with
FOLFIRI alone, aiming at investigating the correlation of
VEGF SNPs with the efficacy of bevacizumab treatment.
It should be underlined that, as stated above, the
cohorts’ inception was retrospective and patients were
not randomized whether receiving the anti-VEGF or
not, therefore, the significance of the interaction test is
affected by the non-randomization bias.
Unfortunately, we were not able to verify the effect of
VEGF -1498 genetic variants on VEGF plasma levels
and tumoral expression due to the unavailability of
baseline plasma samples and tumoral tissues from our
series. Since data from literature are extremely heteroge-
neous, it would be rather interesting to assess such a
correlation in future studies.
As minor comment, in the bevacizumab-group also
mucinous histology is related with shorter PFS and OS
both in the univariate and in the multivariate model, thus
confirming data from literature about the worse prognosis
of mucinous CRCs [27,28]. Since such an association has
not been verified in the historical control group due to a
lack of information about it, no hypothesis may be
advanced with regard to its potential predictive implication.
Conclusions
The identification of a predictor of resistance to anti-
VEGF could be crucial in the therapeutic algorythm of
Table 4 Multivariable Cox regression model, including
significant variables at the univariate analysis, and
survival in bevacizumab-group
Progression Free Survival (N = 111)
Characteristics Adjusted HR 95% CI P
Mucinous histology No 1
Yes 2.45 1.19-4.44 0.016
Previous adjuvant CT No 1
Yes 1.49 0.84-2.63 0.166
Resected primary tumor No 1
Yes 1.59 0.51-3.71 0.383
-1498 C- 1
T/T 2.28 1.16-4.19 0.018
Overall Survival (N = 111)
Characteristics Adjusted HR 95% CI p
Primary tumor Colon 1
Rectum 0.40 0.15-1.60 0.245
Mucinous histology No 1
Yes 4.22 1.60-9.27 0.009
Leukocytosis No 1
Yes 3.02 1.03-10.07 0.043
-1498 C- 1
T/T 2.22 0.54-5.51 0.195
Table 5 Multivariable Cox regression model, including
treatment, VEGF -1498 C/T polymorphism and their
interaction as covariates
Progression Free Survival
Characteristics N Adjusted HR 95% CI P
Treatment FOLFIRI 107 1
FOLFIRI + Beva 111 0.48 0.34-0.73 0.0008
Bevacizumab-Group (N = 111)
-1498 C- 82 1
T/T 29 2.97 1.28-6.59 0.011
Control Group (N = 107)
-1498 C- 80 1
T/T 27 0.71 0.38-1.27 0.235
Overall Survival
Characteristics N Adjusted HR 95% CI P
Treatment FOLFIRI 107 1
FOLFIRI + Beva 111 0.50 0.29-0.94 0.033
Bevacizumab-Group (N = 111)
-1498 C- 82 1
T/T 29 2.60 0.89-8.36 0.081
Control Group (N = 107)
-1498 C- 80 1
T/T 27 0.66 0.31-1.31 0.239
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molecular criteria, could avoid the exposition of
patients unlikely to benefit from bevacizumab to the
risk of toxicities.
At our knowledge, this is the first report to suggest a
significant role for a genetic determinant in predicting
bevacizumab efficacy in mCRC treated with FOLFIRI
plus the anti-VEGF MoAb: patients with VEGF -1498
T/T genotype do not seem to benefit from antiangio-
genic treatment.
Although very promising, considering the above pre-
sented limitations, these results cannot be valued as
immediately applicable into clinical practice. There-
fore, we consider that our data certainly deserve
further investigation. To this aim, it is currently
ongoing a prospective study in mCRC patients treated
with first-line FOLFIRI and bevacizumab, designed
with the aim of revealing a 40% risk reduction in PFS
bearing VEGF -1498 C-variants as compared to those
carrying -1498 T/T genotype. If this ongoing experi-
ence will confirm the hypothesis generated by the pre-
sent retrospective series, it could be appropriate to
conduct an adequately designed phase III randomized
trial in order to definitively validate such preliminary
considerations.
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